The Journal of Immunology, Vol 155, Issue 2 766-775, Copyright © 1995 by American Association of Immunologists

ARTICLES

HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers

B Wizel, R Houghten, P Church, JA Tine, DE Lanar, DM Gordon, WR Ballou, A Sette and SL Hoffman
Malaria Program, Naval Medical Research Institute, Bethesda, MD 20889, USA.

CD8+ CTL specific for the Plasmodium yoelii sporozoite surface protein 2 (PySSP2) protect mice against malaria. For this reason, vaccines designed to induce CTL against P. falciparum SSP2 (PfSSP2) are under development. Optimal development of PfSSP2 as a component of human malaria vaccines requires characterization of HLA class I-restricted CTL against this Ag. For this purpose, PBMC from four HLA-A2+ human volunteers immunized with P. falciparum irradiated sporozoites were stimulated with a recombinant vaccinia virus expressing PfSSP2 and with 35 PfSSP2-derived 15-amino acid peptides containing sequences conforming to HLA-A2 binding motifs. Ag-specific, genetically restricted, CD8+ T cell-dependent cytotoxic activity against autologous target cells transfected with the PfSSP2 gene was demonstrated in the four volunteers. Twelve of the 35 peptides sensitized HLA-A2-matched target cells for lysis by peptide-stimulated effectors. Three volunteers had CTL against 9 of the 12 peptides, and one had no peptide- specific CTL. HLA-A*0201 restriction was confirmed by demonstrating that effectors from the three responders could be stimulated with six different peptides to lyse HLA-A*0201+ T2 cells incubated with the homologous peptides. Peptide-specific, genetically restricted, CD8+ T cell-dependent cytotoxic activity was also demonstrated against two peptides using unstimulated PBMC as effectors. Available data indicate that the motif-bearing sequences in 6 of the 12 positive peptides are conserved among P. falciparum isolates and clones. Demonstration of HLA- A2-restricted CTL responses to multiple PfSSP2-derived peptides, and of circulating activated CTL against PfSSP2 in immune volunteers provide important information for optimal design and evaluation of vaccines containing this pre-erythrocytic stage Ag.

This article has been cited by other articles:

				K. E. Lyke, R. B. Burges, Y. Cissoko, L. Sangare, A. Kone, M. Dao, I. Diarra, M. A. Fernandez-Vina, C. V. Plowe, O. K. Doumbo, et al. HLA-A2 Supertype-Restricted Cell-Mediated Immunity by Peripheral Blood Mononuclear Cells Derived from Malian Children with Severe or Uncomplicated Plasmodium falciparum Malaria and Healthy Controls Infect. Immun., September 1, 2005; 73(9): 5799 - 5808. [Abstract] [Full Text] [PDF]

				L. BenMohamed, A. Thomas, and P. Druilhe Long-Term Multiepitopic Cytotoxic-T-Lymphocyte Responses Induced in Chimpanzees by Combinations of Plasmodium falciparum Liver-Stage Peptides and Lipopeptides Infect. Immun., August 1, 2004; 72(8): 4376 - 4384. [Abstract] [Full Text] [PDF]

				P. Sun, R. Schwenk, K. White, J. A. Stoute, J. Cohen, W. R. Ballou, G. Voss, K. E. Kester, D. G. Heppner, and U. Krzych Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-{gamma} J. Immunol., December 15, 2003; 171(12): 6961 - 6967. [Abstract] [Full Text] [PDF]

				T. C. Luke and S. L. Hoffman Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine J. Exp. Biol., November 1, 2003; 206(21): 3803 - 3808. [Abstract] [Full Text] [PDF]

				K. L. FLANAGAN, T. MWANGI, M. PLEBANSKI, K. ODHIAMBO, A. ROSS, E. SHEU, M. KORTOK, B. LOWE, K. MARSH, and A. V. S. HILL EX VIVO INTERFERON-GAMMA IMMUNE RESPONSE TO THROMBOSPONDIN-RELATED ADHESIVE PROTEIN IN COASTAL KENYANS: LONGEVITY AND RISK OF PLASMODIUM FALCIPARUM INFECTION Am J Trop Med Hyg, April 1, 2003; 68(4): 421 - 430. [Abstract] [Full Text] [PDF]

				A. Kumar, S. Kumar, T. P. Le, S. Southwood, J. Sidney, J. Cohen, A. Sette, and S. L. Hoffman HLA-A*01-Restricted Cytotoxic T-Lymphocyte Epitope from the Plasmodium falciparum Circumsporozoite Protein Infect. Immun., April 1, 2001; 69(4): 2766 - 2771. [Abstract] [Full Text] [PDF]

				O. G. Gomez-Duarte, M. F. Pasetti, A. Santiago, M. B. Sztein, S. L. Hoffman, and M. M. Levine Expression, Extracellular Secretion, and Immunogenicity of the Plasmodium falciparum Sporozoite Surface Protein 2 in Salmonella Vaccine Strains Infect. Immun., February 1, 2001; 69(2): 1192 - 1198. [Abstract] [Full Text] [PDF]

				D. L. Doolan, S. Southwood, R. Chesnut, E. Appella, E. Gomez, A. Richards, Y. I. Higashimoto, A. Maewal, J. Sidney, R. A. Gramzinski, et al. HLA-DR-Promiscuous T Cell Epitopes from Plasmodium falciparum Pre-Erythrocytic-Stage Antigens Restricted by Multiple HLA Class II Alleles J. Immunol., July 15, 2000; 165(2): 1123 - 1137. [Abstract] [Full Text] [PDF]

				M. Aidoo, A. Lalvani, S. C. Gilbert, J. T. Hu, P. Daubersies, N. Hurt, H. C. Whittle, P. Druihle, and A. V. S. Hill Cytotoxic T-Lymphocyte Epitopes for HLA-B53 and Other HLA Types in the Malaria Vaccine Candidate Liver-Stage Antigen 3 Infect. Immun., January 1, 2000; 68(1): 227 - 232. [Abstract] [Full Text] [PDF]

				J. D. Kurtis, D. E. Lanar, M. Opollo, and P. E. Duffy Interleukin-10 Responses to Liver-Stage Antigen 1 Predict Human Resistance to Plasmodium falciparum Infect. Immun., July 1, 1999; 67(7): 3424 - 3429. [Abstract] [Full Text] [PDF]

				R. Wang, D. L. Doolan, Y. Charoenvit, R. C. Hedstrom, M. J. Gardner, P. Hobart, J. Tine, M. Sedegah, V. Fallarme, J. B. Sacci Jr., et al. Simultaneous Induction of Multiple Antigen-Specific Cytotoxic T Lymphocytes in Nonhuman Primates by Immunization with a Mixture of Four Plasmodium falciparum DNA Plasmids Infect. Immun., September 1, 1998; 66(9): 4193 - 4202. [Abstract] [Full Text] [PDF]